CONMED Return On Assets vs Asset Turnover Analysis
CNMD Stock | USD 75.31 0.59 0.79% |
CONMED financial indicator trend analysis is way more than just evaluating CONMED prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CONMED is a good investment. Please check the relationship between CONMED Return On Assets and its Asset Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.
Return On Assets vs Asset Turnover
Return On Assets vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CONMED Return On Assets account and Asset Turnover. At this time, the significance of the direction appears to have strong relationship.
The correlation between CONMED's Return On Assets and Asset Turnover is 0.75. Overlapping area represents the amount of variation of Return On Assets that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of CONMED, assuming nothing else is changed. The correlation between historical values of CONMED's Return On Assets and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Return On Assets of CONMED are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Return On Assets i.e., CONMED's Return On Assets and Asset Turnover go up and down completely randomly.
Correlation Coefficient | 0.75 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Return On Assets
A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from CONMED's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CONMED current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.At present, CONMED's Enterprise Value Over EBITDA is projected to increase based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 24.93, whereas Tax Provision is projected to grow to (26.9 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 568.0M | 571.2M | 643.1M | 675.2M | Total Revenue | 1.0B | 1.0B | 1.2B | 1.3B |
CONMED fundamental ratios Correlations
Click cells to compare fundamentals
CONMED Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CONMED fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.8B | 1.8B | 1.8B | 2.3B | 2.3B | 2.4B | |
Short Long Term Debt Total | 768.8M | 775.9M | 684.7M | 1.1B | 991.3M | 1.0B | |
Other Current Liab | 64.8M | 60.8M | 65.7M | 143.8M | 208.1M | 218.5M | |
Total Current Liabilities | 188.1M | 190.2M | 196.6M | 296.6M | 310.7M | 326.3M | |
Total Stockholder Equity | 710.5M | 709.0M | 785.4M | 745.5M | 834.2M | 428.2M | |
Property Plant And Equipment Net | 118.9M | 111.4M | 108.9M | 115.6M | 137.3M | 92.9M | |
Net Debt | 743.0M | 748.5M | 663.8M | 1.0B | 967.0M | 1.0B | |
Retained Earnings | 470.8M | 457.4M | 496.6M | 412.6M | 452.5M | 246.1M | |
Cash | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 17.2M | |
Non Current Assets Total | 1.4B | 1.3B | 1.3B | 1.7B | 1.7B | 1.8B | |
Non Currrent Assets Other | 102.3M | 96.8M | 98.8M | 93.9M | 79.5M | 83.5M | |
Cash And Short Term Investments | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 17.5M | |
Net Receivables | 189.1M | 177.2M | 183.9M | 191.3M | 242.3M | 254.4M | |
Common Stock Shares Outstanding | 29.5M | 29.5M | 32.2M | 30.0M | 31.5M | 25.9M | |
Liabilities And Stockholders Equity | 1.8B | 1.8B | 1.8B | 2.3B | 2.3B | 2.4B | |
Non Current Liabilities Total | 876.5M | 852.4M | 783.9M | 1.3B | 1.2B | 1.2B | |
Inventory | 164.6M | 194.9M | 231.6M | 332.3M | 318.3M | 334.2M | |
Other Current Assets | 17.8M | 17.3M | 23.8M | 28.6M | 30.8M | 32.3M | |
Other Stockholder Equity | 298.6M | 315.0M | 342.7M | 390.5M | 431.5M | 453.1M | |
Total Liab | 1.1B | 1.0B | 980.6M | 1.6B | 1.5B | 1.5B | |
Property Plant And Equipment Gross | 118.9M | 111.4M | 372.6M | 393.1M | 412.9M | 433.5M | |
Total Current Assets | 397.4M | 416.7M | 460.1M | 581.2M | 615.6M | 646.4M | |
Accumulated Other Comprehensive Income | (59.3M) | (63.7M) | (54.2M) | (57.9M) | (50.2M) | (47.7M) | |
Short Term Debt | 13.6M | 25.9M | 12.2M | 69.7M | 8.2M | 7.8M | |
Intangible Assets | 532.8M | 501.5M | 471.0M | 681.8M | 649.5M | 331.7M | |
Accounts Payable | 56.0M | 53.3M | 58.2M | 73.4M | 88.2M | 92.6M | |
Good Will | 618.0M | 618.4M | 617.5M | 815.4M | 806.8M | 430.8M | |
Other Liab | 104.2M | 102.5M | 98.8M | 258.7M | 297.5M | 312.3M | |
Other Assets | 84.9M | 103.6M | 89.0M | 85.8M | 98.7M | 103.6M | |
Long Term Debt | 755.2M | 734.8M | 672.4M | 985.1M | 973.1M | 1.0B | |
Treasury Stock | (80.7M) | (67.6M) | (54.1M) | (22.8M) | (20.5M) | (21.5M) | |
Property Plant Equipment | 118.9M | 111.4M | 108.9M | 115.6M | 133.0M | 129.3M | |
Current Deferred Revenue | 53.7M | 50.2M | 60.5M | 9.7M | 6.2M | 5.8M | |
Net Tangible Assets | (440.4M) | (410.9M) | (340.8M) | (751.7M) | (676.5M) | (642.7M) | |
Retained Earnings Total Equity | 470.8M | 457.4M | 496.6M | 412.6M | 474.5M | 467.3M | |
Long Term Debt Total | 755.2M | 735.2M | 672.4M | 985.1M | 1.1B | 1.2B | |
Capital Surpluse | 379.3M | 382.6M | 396.8M | 413.2M | 475.2M | 384.5M | |
Deferred Long Term Liab | 74.5M | 57.9M | 68.5M | 66.7M | 60.1M | 72.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is CONMED's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 9.567 | Dividend Share 0.8 | Earnings Share 2.61 | Revenue Per Share 41.046 | Quarterly Revenue Growth 0.057 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.